CORRECTION: Elevance Health Q4 Adjusted EPS $5.62 Misses $5.64 Estimate, Sales $42.45B Beat $42.09B Estimate
Portfolio Pulse from Benzinga Newsdesk
Elevance Health (NYSE:ELV) reported Q4 adjusted EPS of $5.62, slightly missing the consensus estimate of $5.64. However, the company's sales of $42.45B exceeded the estimate of $42.09B. Compared to last year, EPS increased by 7.46% and sales by 7.03%.
January 24, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Elevance Health reported a slight miss on Q4 EPS estimates but exceeded revenue expectations, with year-over-year growth in both metrics.
The slight miss in EPS is generally considered negative for stock performance, but the beat on revenue and the year-over-year growth in both earnings and sales could mitigate any negative impact. The mixed results lead to a neutral short-term score, as the market may weigh the positives against the slight earnings miss.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100